2024 Annual Meeting | Industry Therapeutic Update from Alexion, AstraZeneca Rare Disease: Examining Additional Data Analysis for a Terminal Complement Inhibitor for Adult Patients With Anti-AChR Antibody-Positive gMG

Date Tuesday 04/16/24

Time 11:45 AM - 12:45 PM MDT Add To Calendar

Location Colorado Convention Center | Bluebird 3BC

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Perry Shieh, MD, PhD, FAAN

Topic(s) General Neurology, Autoimmune Neurology

Learning Objectives A case-based exploration examining additional data analyses of a terminal complement inhibitor for adult patients living with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG).
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2024 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
11:45 AM - 12:45 PM MDT	Speaker	Industry Therapeutic Update from Alexion, AstraZeneca Rare Disease: Examining Additional Data Analysis for a Terminal Complement Inhibitor for Adult Patients With Anti-AChR Antibody-Positive gMG

Faculty Disclosures
Perry Shieh, MD, PhD, FAAN	Dr. Shieh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sarepta. Dr. Shieh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Shieh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Shieh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for CSL Behring. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Grifols. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Dr. Shieh has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Biogen. Dr. Shieh has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Argenx. Dr. Shieh has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Catalyst.